Latest News
FDA grants priority review to Takeda's zasocitinib application for plaque psoriasis
14 September 2026 - Japanese pharmaceutical company Takeda (TSE:4502) (NYSE:TAK) said on Monday that the US Food and Drug Administration (FDA) has accepted its new drug application for zasocitinib (TAK-279) under Priority Review for adults with moder...
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
14 September 2026 - Biotechnology company Armata Pharmaceuticals Inc (NYSE American: ARMP) reported on Monday that it has received U.S. Food and Drug Administration Breakthrough Therapy designation for AP-SA02, its intravenous multi-phage product can...
AstraZeneca's Etcamah misses primary endpoint in Phase III breast cancer trial
14 September 2026 - Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN) disclosed on Monday that its Phase III SERENA-4 trial of Etcamah (camizestrant) in combination with palbociclib did not achieve its primary endpoint of a sta...
GSK reports positive Jideytro data supporting potential first-line lung cancer use
14 September 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) on Monday reported positive registrational Phase I/II ARROS-1 data for Jideytro (zidesamtinib) in previously untreated ROS1-positive non-small cell lung cancer (NSCLC), supp...
Eloxx Pharmaceuticals commences Phase 2b study of exaluren
14 September 2026 - Eloxx Pharmaceuticals Inc (Nasdaq:ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, announced on Friday that the first two patients have been dosed in the EXACT Study,...